C section News and Research

RSS

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

AGA announces recipients of its annual recognition awards 2014

The American Gastroenterological Association (AGA) has announced the recipients of its annual recognition awards, given in honor of outstanding contributions and achievements in gastroenterology.

6 May 2014

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 sickened, Congress passed the Compounding Quality Act .

5 May 2014

Important steps that women should take before, during and after pregnancy

Being a mother involves major responsibilities and love. That's why it's important to take steps before, during and after pregnancy.

2 May 2014

Report focuses on behavioral issues linked with patients' self-management of type 2 diabetes

Clinical Therapeutics features a special report in its April issue focusing primarily on the behavioral issues associated with patients' self-management of type 2 diabetes.

29 Apr 2014

Girls labeled fat at age 10 are more likely to be obese at 19, say researchers

Girls who are told by a parent, sibling, friend, classmate or teacher that they are too fat at age 10 are more likely to be obese at age 19, a new study by UCLA psychologists shows.

29 Apr 2014

H2Ocean launches Extreme Tattoo Aftercare Kit

H2Ocean, a leader in developing natural health care products using patented sea salt formulas, is proud to announce the launch of their coveted Extreme Tattoo Aftercare Kit in 5,179 Walgreens stores Nationwide found in the First Aid Section.

26 Apr 2014

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

25 Apr 2014

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes.

23 Apr 2014

Researchers find link between patient satisfaction and SDM during radiation treatment

Playing an active role in their radiation treatment decisions leaves cancer patients feeling more satisfied with their care, and may even relieve psychological distress around the experience, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the journal Cancer.

15 Apr 2014

ABAM Foundation accredits four new addiction medicine fellowship programs

The American Board of Addiction Medicine Foundation today announced the accreditation of four new addiction medicine fellowship programs, bringing the total number of accredited programs to 23.

11 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Parkinson’s patients encouraged to order new Parkinson’s Passport to avoid medicine problems

This World Parkinson’s Day (11 April 2014) Parkinson’s Australia and NPS MedicineWise are encouraging anyone with Parkinson’s — or people caring for someone with the condition — to order a new Parkinson’s Passport to help avoid medicine problems.

9 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

Study examines links between parental obesity and risk of autism developmental in child

Several studies have looked at possible links between maternal obesity during pregnancy and the risk of developmental disorders in the child. However, paternal obesity could be a greater risk factor than maternal obesity, according to a new study from the Norwegian Institute of Public Health.

8 Apr 2014

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Helping doctors monitor their melanoma patients' progress in response to treatment is just one of the many exciting applications of Bio-Rad's Droplet Digital PCR (ddPCR-) technology being showcased at the 2014 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9.

7 Apr 2014

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors.

4 Apr 2014

Managing pregnancy-related complications: an interview with Dr. Mark Zakowski

Pregnancy-related mortality has increased over the last 25 years. Ten years ago the top three pregnancy-related mortality diagnoses were hemorrhage, preeclampsia, and embolism (includes thrombotic and amniotic).

2 Apr 2014

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.